文献速递青光眼

糖原合成酶激酶-3β抑制剂CHIR 99021对转化生长因子β诱导的Tenon囊纤维化的影响

The Effect of CHIR 99021, a Glycogen Synthase Kinase-3β Inhibitor, on Transforming Growth Factor β-Induced Tenon Fibrosis.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2021-01-01

本研究探讨糖原合成酶激酶-3β(GSK-3β)抑制对转化生长因子-β(TGF-β)诱导的人Tenon囊成纤维细胞(HTFs)纤维化的影响。TGF-β处理增加HTFs纤维化相关分子表达,青光眼患者Tenon囊组织中这些分子表达高于正常者;CHIR 99021降低活性GSK-3β及纤维化相关分子,减少Smad2/Smad3磷酸化比例并减弱HTF迁移。结果提示GSK-3β可能是青光眼滤过术后维持滤过泡功能的潜在靶点。

要点

  • TGF-β处理增加HTFs纤维化相关分子表达,青光眼患者Tenon囊组织表达高于正常者。
  • CHIR 99021降低HTFs中活性GSK-3β及TGF-β诱导的纤维化相关分子表达。
  • CHIR 99021减少HTFs中磷酸化Smad2/Smad2与Smad3/Smad3比值并减弱HTF迁移。

核心结论

  • 结果表明GSK-3β抑制可调控TGF-β介导的HTFs纤维化,提示GSK-3β可能是青光眼滤过术后维持滤过泡功能的潜在靶点。

研究设计与样本

  • 实验采用原代培养的HTFs及来自正常受试者和青光眼患者的Tenon囊组织,通过实时定量PCR和Western blot检测纤维化相关分子与GSK-3β表达,并分析CHIR 99021存在下磷酸化Smad2和Smad3水平,用伤口愈合实验检测CHIR 99021对HTFs迁移的影响。

主要发现

  • TGF-β处理导致HTFs纤维化相关分子(纤连蛋白、Iα型胶原、α-平滑肌肌动蛋白)水平增加。
  • 青光眼患者Tenon囊组织中这些纤维化相关分子的表达水平高于正常受试者。
  • TGF-β处理HTFs后观察到活性型GSK-3β(Y216)显著增加。
  • CHIR 99021处理的HTFs中活性型GSK-3β及TGF-β诱导的纤维化相关分子显著降低。
  • CHIR 99021降低HTFs中磷酸化Smad2/Smad2与磷酸化Smad3/Smad3比值,并减弱HTF迁移。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study investigated the effect of glycogen synthase kinase-3β (GSK-3β) inhibition on the fibrosis of human Tenon's fibroblasts (HTFs) induced by transforming growth factor-β (TGF-β). METHODS: Quantitative real-time PCR and Western blot analyses were performed to determine the expression levels of molecules associated with the fibrosis of HTFs by TGF-β (fibronectin, collagen Iα, and α-smooth muscle actin) and GSK-3β. The levels of phosphorylated Smad2 and Smad3 were also analyzed in the presence of the GSK-3β inhibitor CHIR 99021. The wound healing assay was performed to determine the effect of CHIR 99021 on the migration of HTFs. All experiments were conducted using primary cultured HTFs or human tenon tissues obtained from normal subjects and patients with glaucoma. RESULTS: Treatment with TGF-β resulted in an increase in the levels of molecules associated with the fibrosis of HTFs. The expression levels of these molecules were higher in the tenon tissues obtained from patients with glaucoma than those from normal subjects. When the HTFs were treated with TGF-β, a significant increase in the active form of GSK-3β (Y216) was observed. A significant decrease in the active form of GSK-3β and molecules associated with fibrosis by TGF-β was noted in HTFs treated with CHIR 99021. CHIR 99021 treatment reduced the phosphorylated Smad2/Smad2 and phosphorylated Smad3/Smad3 ratios in HTFs and attenuated HTF migration. CONCLUSIONS: Our results demonstrated the effect of GSK-3β inhibition on the regulation of TGF-β-mediated fibrosis of HTFs, suggesting GSK-3β to be a potential target for maintaining bleb function after glaucoma filtration surgery.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Lee SY, Chae MK, Yoon JS, et al. The Effect of CHIR 99021, a Glycogen Synthase Kinase-3β Inhibitor, on Transforming Growth Factor β-Induced Tenon Fibrosis. Invest Ophthalmol Vis Sci. 2021. PMID: 34940783. doi:10.1167/iovs.62.15.25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。